Nasdaq Jumps Over 300 Points Following Comments From Fed Chair Powell
U.S. stocks turned sharply higher toward the end of trading, following comments from Fed Chair Jerome Powell.
Why Leslie’s Shares Are Trading Lower By Over 9%? Here Are 60 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Biophytis S.A. (NASDAQ: BPTS) shares jumped 114% to $0.7496.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) rose 74.1% to $0.2115.
Workday, XPeng, Titan Machinery And Some Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Wednesday. Here are some big stocks recording gains in today’s session.
Earnings Scheduled For November 30, 2022
Companies Reporting Before The Bell
• Seadrill (NYSE:SDRL) is expected to report earnings for its third quarter.
• Build-A-Bear Workshop (NYSE:BBW) is likely to report earnings for its third quarter.
Titan Machinery’s Earnings: A Preview
Titan Machinery (NASDAQ:TITN) is set to give its latest quarterly earnings report on Wednesday, 2022-11-30. Here’s what investors…
$1000 Invested In Titan Machinery 5 Years Ago Would Be Worth This Much Today
Titan Machinery (NASDAQ:TITN) has outperformed the market over the past 5 years by 8.37% on an annualized basis producing an average annual return of 18.54%. Currently, Titan Machinery has a market capitalization of $712.58 million.
Titan Machinery Shares Gain On Solid Q2, Raised FY23 Forecast
Titan Machinery Inc. (NASDAQ:TITN) reported second-quarter FY23 revenue growth of 31.5% year-on-year to $496.54 million, beating the consensus of $439.77…
Alibaba, Zoom Video And 76 Biggest Movers From Yesterday
Gainers
Kaspien Holdings Inc. (NASDAQ: KSPN) shares climbed 161.9% to close at $6.81 on Monday on heavy volume amid mention of the stock on social media.
Why These Casino Stocks Are Moving Lower, Here’s 45 Stocks Moving In Monday’s Mid-Day Session
Gainers
Pliant Therapeutics, Inc. (NASDAQ: PLRX) jumped 112.6% to $18.88 after the company said its treatment for Idiopathic Pulmonary Fibrosis was well tolerated in a Phase 2a study.